Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

• Main Authors: I. V. Dolzhikova (Author), O. V. Zubkova (Author), A. I. Tukhvatulin (Author), A. S. Dzharullaeva (Author), N. M. Tukhvatulina (Author), D. V. Shcheblyakov (Author), M. M. Shmarov (Author), E. A. Tokarskaya (Author), Y. V. Simakova (Author), D. A. Egorova (Author), D. N. Scherbinin (Author), I. L. Tutykhina (Author), A. A. Lysenko (Author), A. V. Kostarnoy (Author), P. G. Gancheva (Author), T. A. Ozharovskaya (Author), B. V. Belugin (Author), L. V. Kolobukhina (Author), V. B. Pantyukhov (Author), S. I. Syromyatnikova (Author), I. V. Shatokhina (Author), T. V. Sizikova (Author), I. G. Rumyantseva (Author), A. F. Andrus (Author), N. V. Boyarskaya (Author), A. N. Voytyuk (Author), V. F. Babira (Author), S. V. Volchikhina (Author), D. A. Kutaev (Author), A. N. Bel'skih (Author), K. V. Zhdanov (Author), S. M. Zakharenko (Author), S. V. Borisevich (Author), D. Y. Logunov (Author), B. S. Naroditsky (Author), A. L. Gintsburg (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ebola hemorrhagic fever, also known as Ebola virus disease or EVD, is one of the most dangerous viral diseases in humans and animals. In this open-label, dose-escalation clinical trial, we assessed the safety, side effects, and immunogenicity of a novel, heterologous prime-boost vaccine against Ebol...